- 询价
- 近岸蛋白(Novoprotein)
- DA028
- 2025年11月27日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 英文名：
Recombinant anti-2019-nCoV NP ScFv
- 保存条件：
24 months from manufacturing at <-20 °C; 1 month, 2 to 8 °C under sterile conditions.
- 规格：
1mg
Recombinant anti-2019-nCoV NP ScFv
Catalog #: DA028
Spcificty: Antibody recognizes 2019-nCoV Nucleocapsid Protein
Product buffer solution: 20mM PB, 150mM NaCl, pH 7.4.
Shelf life and storage: 24 months from manufacturing at <-20 °C; 1 month, 2 to 8 °C under sterile conditions.
Description: Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. N protein packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M. Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.
PARAMETERS TESTED ON EACH LOT
Product appearance: Liquid, may turn slightly opaque during storage.
Product concentration: 5.0 mg/ml (+/- 10 %)
Immunoreactivity: 80-120 % compared to the reference sample in an ELISA test.
Purity: ≥95 %
Immunoreactivity:
Product stability：
Pair recommendations:
Please note that pair recommendations are based on results obtained by our laboratory. Equally good results may be obtained using other pairs and therefore these recommendations are only indicative.
FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Phage Libraries for Generation of Anti-Botulinum scFv Antibodies
The biotechnological generation of high affinity monoclonal antibodies (MAbs) has traditionally involved the production of hybridomas from spleen cells of immunized animals (1 ). This event, together with availability of increasingly
Generation and Screening of a Modular Human scFv Expression Library from Multiple Donors
Human monoclonal antibodies (MAbs) are more suitable than MAbs of animal origin for clinical applications because of lower hypersensitivity reactions, less formation of circulating immune complexes, and lower anti-immunoglobulin responses
Assessing Fc Glycan Heterogeneity of Therapeutic Recombinant Monoclonal Antibodies Using NP-HPLC
Recombinant monoclonal antibodies (rMAbs) are becoming major human therapeutics to treat life-threatening diseases such as cancer. These rMAbs are produced using either in vitro cell culture processes or transgenic technology in animals
技术资料暂无技术资料 索取技术资料
